SERA - NASDAQ

Sera Prognostics, Inc.

SERA·NASDAQ

$2.22

+8.3%

HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$84.78M

EPS-0.6700

P/E Ratio-3.31

Earnings Date08/05/2026

101.93M

Assets

40%

3Y-12.0%

5Y+589.0%

10Y+338.0%

26.52M

Total Liabilities

3Y+53.0%

5Y+124.0%

10Y-80.0%

75.41M

Total Equity

58%

3Y-24.0%

5Y+2465.0%

10Y-171.0%

Sera Prognostics, Inc. Funding & Solvency Profile

SERA · NASDAQ

Current Assets

Cash & Cash Equivalents3.94M

Net Receivables12.00K

Inventory0.00

Other Current Assets1.56M

Total Current Assets41 M

Non-Current Assets

Property, Plant & Equipment1.15M

Goodwill & Intangible Assets910.00K

Long-Term Investments0.00

Other Non-Current Assets59.10M

Total Non-Current Assets60 M

Total Assets

101.93M

Financial Health Analysis

Current Ratio

1.69x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.35x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

17 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

40% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Sera Prognostics, Inc. Balance Sheet

SERA • NASDAQ

Sera Prognostics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3.9M	4M	3.9M	29.9M	58.9M	13.5M	21.4M
Short-Term Investments	35.3M	42.2M	45.2M	52.8M	46.2M	0.0	0.0
Cash & Short-Term Investments	39.2M	46.2M	49.1M	82.7M	105.1M	13.5M	21.4M
Net Receivables	12K	34K	11.5M	6.1M	3.1M	2K	1K
Accounts Receivables	12K	34K	160K	113K	27K	2K	1K
Other Receivables	0.0	0.0	11.3M	6M	3.1M	0.0	0.0
Prepaids	0.0	1.3M	0.0	0.0	2M	198K	161K
Other Current Assets	1.6M	19K	795K	1.3M	0.0	0.0	0.0
Total Current Assets	40.8M	47.6M	61.3M	90.1M	110.3M	13.7M	21.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.1M	1.9M	3.2M	3.1M	1.8M	965K	1.6M
Intangible Assets	910K	1M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	910K	1M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	22M	30.8M	21.3M	34.8M	0.0	0.0
Other Non-Current Assets	59.1M	124K	77K	1.8M	157K	98K	72K
Total Non-Current Assets	61.2M	25M	34.1M	26.2M	36.8M	1.1M	1.7M
Total Assets	101.9M	72.6M	95.4M	116.3M	147M	14.8M	23.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	862K	2M	1M	1.5M	1.2M	441K	748K
Accounts Payable	862K	2M	1M	1.5M	1.2M	441K	748K
Accrued Expenses	0.0	1.4M	1.2M	2.9M	460K	2.4M	1.1M
Short Term Debt	2K	0.0	0.0	0.0	0.0	8M	3.7M
Capital Lease Obligations (Current)	0.0	838K	1M	983K	74K	69K	72K
Deferred Revenue	20.3M	0.0	20.2M	9.1M	3.1M	0.0	1.2M
Other Current Liabilities	3M	20.5M	926K	1.1M	3.6M	321K	294K
Total Current Liabilities	24.2M	24.8M	24.4M	15.5M	8.4M	11.2M	5.9M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	348K	5.4M
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	139K	118.4M
Total Non-Current Liabilities	2.3M	2K	840K	1.8M	54K	614K	124M
Capital Lease Obligations	2.3M	840K	1.9M	2.8M	128K	196K	206K
Total Liabilities	26.5M	24.8M	25.3M	17.4M	8.5M	11.9M	129.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	128.5M	117.6M
Common Stock	4K	3K	3K	3K	3K	0.0	0.0
Additional Paid-In Capital	386.9M	327.5M	317.1M	310.6M	305.2M	5.9M	5M
Retained Earnings	-311.7M	-279.8M	-246.9M	-210.7M	-166.5M	-131.5M	-111.6M
Accumulated Other Comprehensive Income/Loss	262K	60K	-15K	-981K	-183K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	1.0	0.0
Total Stockholders' Equity	75.4M	47.8M	70.2M	98.9M	138.6M	2.9M	-106.6M
Total Equity	75.4M	47.8M	70.2M	98.9M	138.6M	2.9M	-106.6M
SUMMARY
Total Liabilities & Equity	101.9M	72.6M	95.4M	116.3M	147M	14.8M	23.3M
Total Investments	35.3M	64.2M	76M	74.2M	81M	0.0	0.0
Total Debt	2.3M	840K	1.9M	2.8M	128K	8.6M	9.3M
Net Debt	-1.6M	-3.2M	-2M	-27M	-58.8M	-5M	-12.1M
Shares Outstanding	37,094,109	37,094,109	37,094,109	37,094,109	37,094,109	37,094,109	37,094,109

SEC Filings

SERA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 01, 2026	May 26, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	April 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 24, 2025	November 24, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing

Showing 1 to 10 of 79 filings

Related Guides

Blog Categories

Continue your SERA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.